Literature DB >> 24129825

Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification.

Ching-Wei D Tzeng1, Matthew H G Katz, Jason B Fleming, Jeffrey E Lee, Peter W T Pisters, Holly M Holmes, Gauri R Varadhachary, Robert A Wolff, James L Abbruzzese, Jean-Nicolas Vauthey, Thomas A Aloia.   

Abstract

BACKGROUND: We previously described the clinical classification of patients with resectable pancreatic tumor anatomy but marginal performance status (PS) or reversible comorbidities as "borderline resectable type C" (BR-C). This study was designed to analyze the incidence and risk factors for post-pancreaticoduodenectomy (PD) morbidity/mortality in a multi-institutional cohort of BR-C patients.
METHODS: Elective PDs were evaluated from the 2005-10 ACS-NSQIP database. BR-C was defined as age ≥ 80, poor PS, weight loss > 10 %, pulmonary disease, recent myocardial infarction/angina, stroke history, and/or preoperative sepsis. Variables associated with 30-day postoperative major complications (PMC) and mortality were analyzed.
RESULTS: A total of 3,033/8,266 (36.7 %) patients were BR-C. BR-C patients were more likely to suffer PMC (31.3 vs. 26.2 %) and mortality (4.1 vs. 2.3 %). BR-C patients with PMC suffered 50 % higher mortality versus non-BR-C patients with PMC (11.5 vs. 7.7 %) (all p < 0.001). For BR-C patients, multivariate analysis identified the following risk factors for PMC or mortality: albumin < 3.5 g/dL, dyspnea, preoperative sepsis, age ≥ 80, poor PS, anesthesia score ≥ 4, and intraoperative transfusion ≥ 4 units.
CONCLUSIONS: Nationwide, one third of patients undergoing PD are medically borderline. These BR-C patients are at higher risk for and less able to be rescued from PMC. Surgeons should identify and optimize comorbidities and utilize prehabilitation to address functional deficits before elective PD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24129825     DOI: 10.1007/s11605-013-2371-6

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  33 in total

1.  Trends in hospital volume and operative mortality for high-risk surgery.

Authors:  Jonathan F Finks; Nicholas H Osborne; John D Birkmeyer
Journal:  N Engl J Med       Date:  2011-06-02       Impact factor: 91.245

2.  A root-cause analysis of mortality following major pancreatectomy.

Authors:  Charles Mahlon Vollmer; Norberto Sanchez; Stephen Gondek; John McAuliffe; Tara S Kent; John D Christein; Mark P Callery
Journal:  J Gastrointest Surg       Date:  2011-11-08       Impact factor: 3.452

3.  One thousand consecutive pancreaticoduodenectomies.

Authors:  John L Cameron; Taylor S Riall; JoAnn Coleman; Kenneth A Belcher
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

4.  Postoperative morbidity index: a quantitative measure of severity of postoperative complications.

Authors:  Steven M Strasberg; Bruce L Hall
Journal:  J Am Coll Surg       Date:  2011-08-25       Impact factor: 6.113

5.  Preoperative factors predict perioperative morbidity and mortality after pancreaticoduodenectomy.

Authors:  David Yu Greenblatt; Kaitlyn J Kelly; Victoria Rajamanickam; Yin Wan; Todd Hanson; Robert Rettammel; Emily R Winslow; Clifford S Cho; Sharon M Weber
Journal:  Ann Surg Oncol       Date:  2011-02-20       Impact factor: 5.344

6.  Pancreaticoduodenectomy can be performed safely in patients aged 80 years and older.

Authors:  Minna K Lee; Joseph Dinorcia; Patrick L Reavey; Marc M Holden; Jeanine M Genkinger; James A Lee; Beth A Schrope; John A Chabot; John D Allendorf
Journal:  J Gastrointest Surg       Date:  2010-09-08       Impact factor: 3.452

7.  Pancreatic or liver resection for malignancy is safe and effective for the elderly.

Authors:  Y Fong; L H Blumgart; J G Fortner; M F Brennan
Journal:  Ann Surg       Date:  1995-10       Impact factor: 12.969

8.  Intraoperative transfusion of 1 U to 2 U packed red blood cells is associated with increased 30-day mortality, surgical-site infection, pneumonia, and sepsis in general surgery patients.

Authors:  Andrew C Bernard; Daniel L Davenport; Phillip K Chang; Taylor B Vaughan; Joseph B Zwischenberger
Journal:  J Am Coll Surg       Date:  2009-03-26       Impact factor: 6.113

9.  Assessment of pancreatic cancer care in the United States based on formally developed quality indicators.

Authors:  Karl Y Bilimoria; David J Bentrem; Keith D Lillemoe; Mark S Talamonti; Clifford Y Ko
Journal:  J Natl Cancer Inst       Date:  2009-06-09       Impact factor: 13.506

10.  Immunonutrition for patients undergoing elective surgery for gastrointestinal cancer: impact on hospital costs.

Authors:  Josephine A Mauskopf; Sean D Candrilli; Hélène Chevrou-Séverac; Juan B Ochoa
Journal:  World J Surg Oncol       Date:  2012-07-06       Impact factor: 2.754

View more
  11 in total

1.  The Landmark Series: Preoperative Therapy for Pancreatic Cancer.

Authors:  Sameer H Patel; Matthew H G Katz; Syed A Ahmad
Journal:  Ann Surg Oncol       Date:  2021-05-28       Impact factor: 5.344

2.  Gallbladder perforation: morbidity, mortality and preoperative risk prediction.

Authors:  F Ausania; S Guzman Suarez; H Alvarez Garcia; P Senra del Rio; E Casal Nuñez
Journal:  Surg Endosc       Date:  2014-08-27       Impact factor: 4.584

Review 3.  Neoadjuvant therapy for pancreas cancer: past lessons and future therapies.

Authors:  Jeffrey M Sutton; Daniel E Abbott
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 4.  A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review.

Authors:  Evan L Fogel; Safi Shahda; Kumar Sandrasegaran; John DeWitt; Jeffrey J Easler; David M Agarwal; Mackenzie Eagleson; Nicholas J Zyromski; Michael G House; Susannah Ellsworth; Ihab El Hajj; Bert H O'Neil; Attila Nakeeb; Stuart Sherman
Journal:  Am J Gastroenterol       Date:  2017-01-31       Impact factor: 10.864

5.  Vascular Resections in Association With Pancreatic Resections for Locally Advanced Pancreatic Cancer.

Authors:  Nicolae Bacalbasa; Irina Balescu; Ion Barbu; Ovidiu Stiru; Cornel Savu; Lucian Pop; Adnan Al Aloul; Bogdan Ursut; Vladislav Brasoveanu; Sorin Petrea
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

6.  Modified binding pancreaticogastrostomy vs modified Blumgart pancreaticojejunostomy after laparoscopic pancreaticoduodenectomy for pancreatic or periampullary tumors.

Authors:  Satyaprakash Ray Choudhury; Raja Kalayarasan; Senthil Gnanasekaran; Biju Pottakkat
Journal:  World J Clin Oncol       Date:  2022-05-24

7.  Increased morbidity and mortality of a concomitant colectomy during a pancreaticoduodenectomy: an NSQIP propensity-score matched analysis.

Authors:  Jennifer W Harris; Jeremiah T Martin; Erin C Maynard; Patrick C McGrath; Ching-Wei D Tzeng
Journal:  HPB (Oxford)       Date:  2015-07-30       Impact factor: 3.647

8.  Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus on the 2017 Definition of Borderline Resectable Cancer.

Authors:  Aoi Hayasaki; Shuji Isaji; Masashi Kishiwada; Takehiro Fujii; Yusuke Iizawa; Hiroyuki Kato; Akihiro Tanemura; Yasuhiro Murata; Yoshinori Azumi; Naohisa Kuriyama; Shugo Mizuno; Masanobu Usui; Hiroyuki Sakurai
Journal:  Cancers (Basel)       Date:  2018-03-05       Impact factor: 6.639

9.  The Systemic Inflammation-Based Prognostic Score Predicts Postoperative Complications in Patients Undergoing Pancreaticoduodenectomy.

Authors:  Guangzhen Qu; Dong Wang; Weiyu Xu; Kai Wu; Wei Guo
Journal:  Int J Gen Med       Date:  2021-03-09

10.  Effects of body mass index and serum albumin on overall survival in patients with cancer undergoing pancreaticoduodenectomy: a single-center retrospective cohort study.

Authors:  Lei Cui; Huiping Yu; Qingmei Sun; Yi Miao; Kuirong Jiang; Xiaoping Fang
Journal:  World J Surg Oncol       Date:  2022-07-01       Impact factor: 3.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.